Redeye: Biovica - A Further Take on a TK1 Pioneer

Redeye views the completed analytical validation as a confirmation that the development of the DiviTum cancer diagnostic test is on track, with sights on a potential FDA clearance in the beginning of next year. We increase likelihood of approval. Also, we have reviewed our cost forecasts taking a more positive stance on margins in a partnering structure. We raise our base case to SEK 31 (24).

Read more and download the Research Update

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.